Simcere Pharmaceutical Group Limited (HK:2096) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Simcere Pharmaceutical Group Limited has announced that their Sanbexin sublingual tablets received the U.S. FDA’s Breakthrough Therapy designation for acute ischemic stroke treatment. This designation is expected to expedite the development and review process, significantly reducing the time for marketing approval. The drug, which is currently under review in China and has completed Phase I trials in the U.S., promises to improve stroke treatment with its quick-absorption formula.
For further insights into HK:2096 stock, check out TipRanks’ Stock Analysis page.